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Abstract
Background: In the many descriptive studies on prescribed psychotropic drug use by community-
dwelling older persons, several sociodemographic and other factors associated with drug use
receive inconsistent support.
Method: Empirical reports with data on at least benzodiazepine or antidepressant drug use in
samples of older persons published between 1990 and 2001 (n = 32) were identified from major
databases and analyzed to determine which factors are most frequently associated with
psychotropic drug use in multivariate analyses. Methodological aspects were also examined.
Results: Most reports used probability samples of users and non-users and employed cross-
sectional designs. Among variables considered in 5 or more reports, race, proximity to health
centers, medical consultations, sleep complaints, and health perception were virtually always
associated to drug use. Gender, mental health, and physical health status were associated in about
two-thirds of reports. Associations with age, marital status, medication coverage, socioeconomic
status, and social support were usually not observed.
Conclusions: The large variety of methods to operationalize drug use, mental health status, and
social support probably affected the magnitude of observed relationships. Employing longitudinal
designs and distinguishing short-term from long-term use, focusing on samples of drug users
exclusively, defining drug use and drug classes more uniformly, and utilizing measures of
psychological well-being rather than only of distress, might clarify the nature of observed
associations and the direction of causality. Few studies tested specific hypotheses. Most studies
focused on individual characteristics of respondents, neglecting the potential contribution of health
care professionals to the phenomenon of psychotropic drug use among seniors.
Background
The use of prescribed psychotropic drugs by older persons
has been a subject of interest for several decades [1,2]. Psy-
chotropic drugs are defined as substances that act directly
on the central nervous system, affecting mood, cognition,
and behavior, and usually include anxiolytics, sedatives
and hypnotics, antidepressants, neuroleptics, anticonvul-
sants, and stimulants. The topic continues to draw
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researchers' attention for several reasons, including (1)
the high prevalence of older users (especially of benzodi-
azepines) and their typically long-term consumption, (2)
their special vulnerability to drug induced iatrogenesis,
(3) the discrepancy between rates of mental disorder and
rates of drug use among older people, and (4) inappropri-
ate prescribing.
The prevalence of psychotropic drug use among commu-
nity-dwelling older persons (usually defined as those 65
years and older) varies from about 20% to 48% [3-5].
More than half of them take psychotropics for six months
or longer, and are therefore considered long-term users
[4,6,7]. For example, 69% of Canadian elders using ben-
zodiazepines have done so for at least a year [3]. Long-
term use is contraindicated because benzodiazepines lack
effectiveness beyond a few weeks or months of sustained
use for their principal indications, the relief of insomnia
and anxiety [8-17].
Since aging increases the likelihood of drug accumulation
and intoxication, older persons are particularly vulnerable
to adverse effects from psychotropic drugs [18]. Notable
harmful consequences of psychotropic drug use include
memory impairment, psychomotor slowing, delirium,
falls with a risk of hip fracture, automobile accidents, and
psychiatric hospitalizations [19-21].
Although more psychotropic drug users are found among
older persons than any other age group, the prevalence of
mental disorders appears to be lower among older than
younger adults. This has been shown for major depres-
sion, anxiety disorders and sleep disorders [6,22-30].
Other observations, such as the small rate of hospital
admissions for psychiatric reasons among older persons
(1.1%) [4] compared to their high rate of psychotropic
drug use relative to younger adults' rate, confirm these
findings.
The inappropriate prescription of psychotropic drugs may
account partially for the discrepancy between low levels of
distress and high levels of drug use among older persons.
Inappropriate prescriptions include questionable drug
combinations (such as two benzodiazepines), excessive
treatment duration, and drugs contraindicated for use by
older people (such as long half-life benzodiazepines).
Authors estimate that one-fifth to one-half of psycho-
tropic drug prescriptions to the elderly are "inappropri-
ate" [4,16,31,32].
These findings suggest that older persons' psychological
well-being is not the principal determinant of their psy-
chotropic drug use. In the present article, we review recent
empirical studies in order to identify other factors that
may account for psychotropic drug use among older per-
sons. A large body of work bears on this age group and
their use of psychotropic and other drugs [33,34]. Earlier
reviews examined prevalence rates [35-39], the issues of
long-term use [40] and dependence [41,42], as well as var-
ious models of drug use [43,44]. However, to our knowl-
edge none focuses on community-dwelling psychotropic
drug users. Consequently, the present review critically
examines various factors associated with such drug use
among this population. Each factor is discussed in terms
of the empirical support it has received, of hypotheses put
forth to explain its association with drug use, and of sug-
gestions for future research.
Methods
Reports were selected on April 20, 2001, from the follow-
ing bibliographic databases: MedLine, Cumulative Index to
Nursing & Allied Health Literature, Psychlit, Eric and Socio-
logical Abstracts for the years 1990 to 2001. Various key-
words were used. Selected reports had to: (1)constitute
either a peer-reviewed journal article or a government
publication published in English or French; (2) present
specific retrievable empirical results concerning older per-
sons, regardless of other age groups studied (some reports
[16,39,45] were rejected because of this criterion); (3)
report on non-institutionalized, community-dwelling
participants at the time of the study; and (4) provide spe-
cific results on at least benzodiazepine or antidepressant
drug use, regardless of other drug classes studied (some
reports [29,46,47] were rejected because of this criterion).
A total of 61citations met these criteria in the databases.
Eliminating overlaps left only 32 separate reports, all of
which were retrieved and are included in this review. Their
reference lists were also consulted, but no other study was
identified by this mean.
The 32 publications report on 30 different studies con-
ducted in ten different countries. Unless indicated other-
wise, each report is treated as a separate study. Most
reports originated from the United States (31%) and Can-
ada (28%), followed by France (12.5%), Sweden (9.5%),
and 3% each (one report) from Australia, Austria, Ireland,
the Netherlands, Spain, and the United Kingdom (Table 1
[see additional file 1]). Of 26 reports that disclosed a
source of funding, 16 (61.5%) identified government
agencies, 6 (23%) government-industry or government-
foundation partnerships, and 4 (15.5%) industry. Most
studies (62%) collected their data during the 1990s, but
several did so during the 1980s (34%) and 1970s (3%). As
far as could be determined, the median time from end of
data collection to publication was 6 years (range: 1 – 12
years).
Most reports (24, 75%) presented multivariate data anal-
yses, usually multivariate logistic regression, where the
independent contribution of various variables to theBMC Nursing 2004, 3:3 http://www.biomedcentral.com/1472-6955/3/3
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variance in psychotropic drug use could be ascertained
while controlling for the contribution of other variables.
Although variables with statistically significant associa-
tions (p < .05) to drug use that remained in the regression
equation were often considered "predictors," strictly
speaking only an association is demonstrated in this fash-
ion, and the direction of causality can rarely be estab-
lished. This is especially so when a theoretical model is
not specified prior to the data analysis, as was the case in
the vast majority of reports. The eight remaining studies
conducted bivariate analyses solely, and most examined
three or less variables.
In the following review, associations of sociodemographic
factors and life conditions with psychotropic drug use are
examined first. A factor was deemed well supported by the
review studies when 70% of the results from all studies
that considered this factor were statistically significant and
pointed in the same direction. Second, methodological
and conceptual issues relevant to the study of psycho-
tropic drug use among the elderly, and salient in the
reviewed studies, are discussed.
Results
Psychotropic drug use and sociodemographic 
characteristics
Prevalence of psychotropic drug use
Weighted average prevalence rates of psychotropic drug
use were estimated from all reports having collected data
from probability samples or entire populations (n = 22).
In longitudinal studies, data from the last year of the study
were used. Average prevalence of any psychotropic drug
use from 9 studies was 29.0% (range 11.8% – 42.5%). For
drugs identified in the reports as benzodiazepines, minor
tranquilizers, anxiolytics, or sedative-hypnotics, the aver-
age prevalence in 13 studies was 21.5% (range 6% –
43.8%). In 11 studies with data on antidepressants, the
average prevalence was 6.9% (range 2.3% – 14%). Finally,
for neuroleptics, it was 3.1% (6 studies, range 1% to 6%).
Age
Older people are more likely than any other age group to
use any type of medication [29]. However, it has been
observed that medication use decreases in those over 75
years [4]. Some suggest that this occurs because: doctors
exercise more caution when prescribing to the oldest old
[48,49], survivors into advanced age are healthier and
thus use fewer medications [4,50], the elderly face fewer
stressful events [50]. The observation of a decline in psy-
chotropic drug use with very advancing age is not univer-
sal [51]: Blazer et al. [6] and Mamdani et al.[49] found
that it reaches its peak prevalence among those older than
85 years. As Table 2 [see additional file 2] shows, 22 stud-
ies carried out 23 tests of the association between age and
drug use, but only 8 (35%) of the results showed an age-
specific trend (5 found an increase and 3 a decrease). This
low percentage prevents firm conclusions about any age
trend in regard to psychotropic drug use among older
people.
Gender
Over the past three decades, numerous hypotheses have
been proposed to explain the higher prevalence of psy-
chotropic drug use among women than men: women are
more inclined to reveal their emotional problems to their
doctor[35,36,52-55], to request prescriptions explicitly
[36,54,55], to hold more positive views of psychotropic
drugs [50]. Some authors have suggested that men prefer
to use alcohol rather than prescribed drugs to deal with
emotional problems [56,57]. Graham and colleagues [42]
failed to support this last hypothesis in a sample of 826
older persons. Other authors suggest that since women
live longer than men, they experience more effects of
aging, losses and health problems, all of which increase
their likelihood of using a psychotropic [37,49,55,58].
Physicians might be more willing to prescribe a psycho-
tropic drug to a woman than to a man [49,54,55,59].
Also, women visit physicians more often, increasing their
chance of receiving a prescription [36,55,57]. However, in
studies using population-wide databases, Brown et
al.[60], Jorm et al.[55], and Weyerer and Dilling [45] con-
trolled both the number of health problems and physi-
cian visits and showed that women still used more
psychotropic drugs than men. Kirby et al. [53] found the
same result when controlling for mental health status.
Contradictory results are reported by Mayer-Oakes et al.,
[61] and Swartz et al., [62] who showed the use of benzo-
diazepines to be associated not to gender but to physical
health status, poorer in women than in men.
In this review, 73% of the relevant studies support the
established finding that women are more likely to use psy-
chotropic drugs than men. In two studies, the relationship
with gender holds only among those aged between 65 and
74 years, and in a third, the results are opposite. However,
the studies shed little light on reasons for this disparity.
Only two studies identified as a secondary objective to
look at the gender issue in relation to psychotropic drug
use [42,49]. A few studies tested hypotheses to examine
the role of physical health status and mental health status
relative to gender among seniors, but none received con-
sistent support [42,45,53,55,60-62]. No other hypothesis
was directly tested in this body of studies. Some authors
borrowed hypotheses from studies with middle-aged
adults to discuss their results [49,53,55,63]. Authors in
other studies which found a statistically significant rela-
tionship between gender and psychotropic drug use did
not discuss or interpret the association [6,48,55,60,64-
74]. In sum, many studies confirm that more women thanBMC Nursing 2004, 3:3 http://www.biomedcentral.com/1472-6955/3/3
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men use psychotropic drugs, but no single compelling
explanation for this difference among the aged emerges
from this body of studies.
Race
The role of culture, ethnicity, and race has received little
attention so far in the literature on older persons' psycho-
tropic drug use. Explaining cultural, ethnic, or racial dis-
parities in use of health services is a complex endeavor,
requiring analysis of predisposing, structural, access, and
other variables in interaction [75-78]. In this review, two
studies from Canada compared likelihood of use among
French and English speakers, one finding an association
with French speakers, albeit in a non-probability sample
[79]. In addition, six studies from the United States com-
pared the prevalence rate of psychotropic drug use
between Whites and African-Americans. All studies but
one controlled for income or education, and all found
that Whites are significantly more likely to use psycho-
tropic drugs. These results concur with many findings
showing differential use of health services along racial and
ethnic lines in the United States [75].
Interpretations of the race-specific findings from these six
studies focused mostly on professional-and individual-
level determinants. Brown et al. [60] suggested that doc-
tors prescribe fewer psychotropic drugs to older African-
Americans by prudence, since the former are more sensi-
tive to some drug effects. Other authors proposed that dif-
ferent prescription patterns result from differences in the
expression of psychological distress [62,80] or from the
lower rate of depression among African-Americans [6].
The smaller proportion of African-Americans and other
minorities in the United States with private health insur-
ance also may play a role, especially with regard to newer,
more expensive drugs [81]. In that country, more studies
are needed to test these hypotheses and others involving
structural and access variables, also with other significant
minority groups such as Latinos. Beyond racial or ethnic
status, studies are needed to understand whether distinct
cultural attitudes independently predict psychotropic
drug use among older people after various sociodemo-
graphic and structural variables are controlled.
Marital status
It has been suggested that older widows would be more
likely to use psychotropic drugs because of the distress of
bereavement [82]. Eleven of 32 studies examined psycho-
tropic drug use in relation to marital status, but only 4
(36%) confirmed an association between drug use and
not being married (single, widowed, divorced, or sepa-
rated). A spouse's death, especially if preceded by long ill-
ness, is likely to represent a significant stressful event
accompanied by insomnia, anxiety or depression for any
person and this can lead to psychotropic drug use. How-
ever, strictly speaking, stressful events or psychological
distress rather than marital status as such would be impli-
cated, and perhaps only on a relatively short-term basis. In
summary, marital status so far is not revealed as a signifi-
cant factor accounting for psychotropic drug use in older
people.
Socioeconomic status
Living in deprived environments and having an unskilled
occupation, low income and little formal education are
variables associated with psychological distress among
adults, and it might be assumed that the same would hold
among older people. However, the studies reviewed fail to
support this association. Socioeconomic status (SES) is
typically operationalized by education, income, and occu-
pation. As Table 2 [see additional file 1] shows, 13 studies
examined one of more of these variables. Lower education
was significantly associated with drug use in only 3 of 11
results (27%). Lower income was significantly associated
with drug use in 3 of 7 results (43%). Two studies exam-
ining occupational status before retirement found an
association: one found that the self-employed were less
likely to use psychotropics [83], the other, using a non-
probability sample, found more blue-collar workers
among users [79]. In sum, most studies did not support
the impact of lower educational level or lower income on
psychotropic drug use among older persons. The sparse
findings regarding occupation are difficult to interpret.
While the importance of SES as a predisposing or mediat-
ing influence on drug use might be more established in
general population studies, it may be less relevant in the
older age group because of a lower rate of psychological
distress and greater access to income security plans and
retirement pensions that prevent extreme poverty.
Insurance status
In the United States and until recently in Canada, older
persons benefited from Medicare or provincial health
insurance plans without medication coverage. Insurance
coverage has been shown to influence psychotropic drug
use by the elderly [84]. Five studies in this review (four
from the USA and one from Canada) examined this issue
in six different tests but only two (33%) supported a rela-
tionship between having insurance coverage for medica-
tion and being more likely to use psychotropic drugs.
Besides the fact that the most frequent psychotropic drugs
used by older persons during the time period covered by
the 32 studies in this review (for example, benzodi-
azepines like lorazepam or tricyclic antidepressants) were
available in inexpensive generic versions, no compelling
hypothesis exists to account for these results. However,
newer psychotropics, such as selective serotonin reuptake
inhibitors which reached peak usage during the late
1990s, have been marketed at much higher prices, and theBMC Nursing 2004, 3:3 http://www.biomedcentral.com/1472-6955/3/3
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impact of insurance coverage on their use might be shown
to differ in future studies.
Proximity to health centers
No study examined meso-level variables related to SES,
such as census-tract or neighborhood poverty, except
proximity to health centers. The use of health services,
including medications, may be increased by proximity to
such services [85]. Close or easy availability of health serv-
ices augments medical consultations (and consequently
the request of medication or its prescription). This
hypothesis is supported in six of seven studies (85%) in
the present review.
Life conditions
Stressful events
Stressful events may increase people's likelihood of using
psychotropic drugs. Only three studies examined this rela-
tionship, each reporting a different result: a positive asso-
ciation [65], a negative association [50], and no
association [79]. The precise role of stressful events within
a model of psychotropic drug use by older persons clearly
needs to be elucidated. To explain the mixed results,
future research might consider the transformation of stres-
sors over time: stressful events may impact significantly
on the initiation of psychotropic drug use, but may recede
to a negligible level in long-term consumption. A longitu-
dinal design is needed to examine this relationship more
adequately, but unfortunately none of the 12 longitudinal
studies in this review explored stressful events in relation
to psychotropic drug use.
Illnesses and other medications
A recent qualitative synthesis of the literature concludes
that the pathway to psychotropic drug use among older
people typically includes the presence of organic disease
[86] (and loneliness, see ahead). Since elderly people suf-
fer from more diseases than younger people, they might
use more psychotropic and of course non-psychotropic
medications. In another vein, some anxious elderly users
of psychotropic drugs might worry excessively about their
health and be more likely to consult physicians and
receive other medications [85].
In this review, nine of 16 studies (56%) found a signifi-
cant association between the presence or the number of
physical illnesses and psychotropic drug use. In their con-
ceptual model, Gustaffson et al. [69] suggest that afflic-
tion by a new disease constitutes a stressful event that
worsens an older person's mental health status, leading to
the need (personally or professionally perceived) for a
psychotropic drug. Nonetheless, the results overall are
equivocal, perhaps because researchers neglected to con-
sider both the type and the duration of health problems.
For example, living with high blood pressure and being
struck with congestive heart failure are dissimilar experi-
ences. Typically, researchers counted only the presence or
number of illnesses and did not distinguish between indi-
viduals who have been living with a disease for a long
period of time and those recently experiencing it. As actu-
ally measured, the illness factor did not clearly discrimi-
nate between older users and non-users of psychotropic
drugs. Taking into account both the nature and the dura-
tion of illnesses in future studies might better elucidate
the relationship between health status and psychotropic
drug use.
Four of six studies (60%) examining the relationship
between psychotropic drug use and use of other medica-
tions found a significantly positive association, but the
direction of causality remains unclear.
Health perception
Health perception–the self-evaluation of one own's
health–has been shown to be more strongly associated
with psychotropic drug use than actual diagnosis of dis-
ease [33]. Some researchers see here an indirect relation-
ship, where poor health perception negatively influences
the mental health status of a person, which in turn leads
to the request for psychotropic drugs [65,69]. Previous
studies support the correlation between mental health sta-
tus and health perception [87-90].
In this review, seven of eight studies (87.5%) examining
the association between health perception and drug use
found a positive relationship. However, two thirds of the
reviewed studies were cross-sectional, preventing conclu-
sions about cause-effect relationship, and typically more
than 80% of the psychotropic drugs used by their subjects
were benzodiazepines. This raises the possibility that
some subjects had poor health perception as a result of
benzodiazepine consumption. Iatrogenic effects of long
term benzodiazepine use may worsen health and func-
tional capacity, hence health perception [73,91]. The
present findings confirm that health perception has a
place within a model of psychotropic drug use among the
elderly, yet leave its precise role unclear. A longitudinal
study would help to elucidate this role.
Social support
It has previously been proposed that low social support is
associated with psychotropic drug use among older peo-
ple [92,93]. In 10 studies here reviewed, various scales
operationalized constructs identified as social support,
social network, social relationships, family relationships,
and social isolation. A variable of living alone or with oth-
ers was included in two of these studies, and subjective
reports of loneliness in two studies. However, in 13 tests
of the association between some of these variables and
drug use, 9 results (69%) failed to observe any significantBMC Nursing 2004, 3:3 http://www.biomedcentral.com/1472-6955/3/3
Page 6 of 13
(page number not for citation purposes)
relationship. All five tests of association with "social sup-
port" and all three tests of association with "social rela-
tionships" found no relationship with drug use. The
single association of "social relationships" was positive, as
was one of two of "living alone." Overall, results are coun-
ter-intuitive since one would expect that without signifi-
cant social support to aid in time of difficulties, a person
might be more likely to seek medical help, increasing the
chances of receiving a drug prescription.
Either social support is a minor strand in the tapestry of
psychotropic drug use, or the concept of social support
may be inadequately operationalized by standard scales.
These may need to measure, beyond frequency of social
contacts and residential status, subjective judgments of
loneliness and of opportunities for social intimacy.
Whereas a summed scale score indicating "social isola-
tion" was not associated with benzodiazepine use in one
study [61], in both studies where the older person's feel-
ing of "loneliness" as such was elicited, its association
with psychotropic drug use was found to be significant
after controlling for other variables, including "social sup-
port" scores [69,70]. Rather than the presence or extent of
social support, a subjective feeling of loneliness may
influence, directly or indirectly, psychotropic drug use
[86].
Mental health status
The association between a diagnosis or rating of mental
disorder or psychological distress and the use of psycho-
tropic drugs is evidently anticipated. In 18 studies, 22 tests
of this association were carried out, and it was significant
in 17 (77%). An intriguing observation is that two of the
four studies that failed to support the association included
only the antidepressant drug class [67,71]. While the asso-
ciation between mental health and psychotropic drug
consumption is well supported, it is worth noting that the
magnitude of the association varies considerably across
studies. The following two pairs of longitudinal and cross-
sectional large-sample studies using multivariate logistic
regression analysis illustrate this variability: benzodi-
azepine users were 2.13 times more likely than non-users
to report depressive symptoms at 10-year follow-up [6],
and 6.7 more likely to report emotional or nervous prob-
lems [63]. Psychotropic drug users were 2.78 times more
likely to report depressive symptoms at 6-year follow-up
[68], and 4 times more likely to report anxious or depres-
sive symptoms [94] (Table 1). We discuss ahead how this
variability may stem from methodological differences,
especially in the measurement of the key variables in the
associations.
Sleep
In the general population, Ohayon and Caulet [28] have
clearly shown that a sleep disorder, such as primary
insomnia diagnosed according to DSM-III-R criteria [95],
is associated with the use of psychotropic drugs. These
authors also noted that complaints of poor or inadequate
sleep were associated with drug use. In the present review,
all five studies (100%) that evaluated this latter associa-
tion among older persons supported it. Although as men-
tioned earlier they do not report more sleep problems
than younger persons, the presence of sleep complaints
appears to play an important role in their psychotropic
drug use.
Medical consultations
The number of annual visits to a doctor's office has an
obvious influence on the number of prescriptions since it
has been shown that up to 75% of visits by older people
end up with a prescription [96,97]. All seven studies
(100%) having examined this factor in this review sup-
ported its association with psychotropic drug use. Because
no drug can be prescribed without the active participation
of a physician, the physician's role is undoubtedly critical.
However, it might differ over time. It has been previously
suggested [98] that the first prescription of a benzodi-
azepine drug and the renewal prescription are two sepa-
rate phenomena: the doctor might be more directive
during the visit leading to the first prescription, whereas
the older patient might be more directive to ensure its
renewal. Thus, the physician's role in psychotropic drug
use among community-dwelling older persons might best
be modelled according to the duration of use. In previous
research, several characteristics of physicians, notably a
high number of consultations, have been significantly
associated with the likelihood of prescribing psychotrop-
ics to older patients [99].
Summary of findings on sociodemographic factors and life conditions
Among the 16 factors identified in this review of 32
empirical reports, only the variables of language and
stressful events were examined in less than five different
studies. Gender, age, and mental health status were most
frequently examined. The variables of race, medical con-
sultations, proximity to health centers, sleep complaints
and health perception are significantly associated with
drug use in all or almost all studies incorporating them.
Gender and mental health status are associated with drug
use in over 70% of studies, while physical illness and
number of medications are associated in slightly over half
of relevant studies. However, significant associations with
age, marital status, socioeconomic status, and social sup-
port are observed in only 27% to 36% of studies in which
these factors are examined.
Methodological issues in the study of psychotropic drug 
use by the elderly
Conflicting results could be explained partially by meth-
odological and conceptual characteristics of many of theBMC Nursing 2004, 3:3 http://www.biomedcentral.com/1472-6955/3/3
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studies reviewed. The following discussion focuses on
study design, sample, concept definitions and measure-
ments (particularly of mental health status and psycho-
tropic drug use), as well as distinction between short-and
long-term psychotropic drug use. Table 1 [see additional
file 1] lists these and other methodological characteristics
of the studies reviewed, as well as summaries of findings
on prevalence of psychotropic drug use.
Design
Descriptive methods (100%) using cross-sectional data
(62%) predominate in this body of recent reports of psy-
chotropic drug use in the elderly. Cross-sectional data are
vulnerable to sample bias, especially when respondents
are not randomly selected, as was the case in 9 of 30
(30%) studies. Given the greater costs involved, the pro-
portion of longitudinal research (38%) seems respectable.
Possibly because of cost factors, these studies examined
fewer variables in relation to psychotropic drug use. How-
ever, besides highlighting the phenomenon of long-term
use of psychotropic drugs by the elderly [55], they pro-
vided clear demonstrations of the deleterious effect of psy-
chotropic drug consumption on cognitive capacities [19]
and of how nursing home admission increases psycho-
tropic drug prescriptions [5], for example. Despite their
greater cost and demanding logistics, longitudinal designs
are essential to understand more accurately how and why
an older person begins, ceases, continues, and modulates
psychotropic drug use. Finally, the absence of qualitative
studies, which usually allow for a better grasp of elderly
users' own perspectives on their use, is noteworthy; most
studies so far have reflected only the researchers' points of
view.
Samples
Virtually all samples (29 in the 30 distinct studies) were
composed of older consumers and non-consumers of psy-
chotropic drugs. Comparisons between these two groups
allow researchers to identify what differentiates users from
non-users of psychotropic drugs. However, one notices
from this review that researchers do not always succeed.
One possible reason may be that short-and long-term
users are combined in one group. Indeed, in almost every
study it appears that investigators are comparing long-
term users with non users. About 20% to 30% of commu-
nity-dwelling older persons use psychotropic drugs
[3,84], with over two-thirds having been users for more
than a year, and over one half for more than one year.
Among the very old, up to 93% have consumed for more
than a year [100]. Thus, the characteristics of users with
less than six months of use are not well known. In one
longitudinal study, the one factor that most accurately dis-
tinguished long-term users of psychotropic drugs from
non-users was having been a user of the drug at the first
measurement three years earlier [68]. The researchers
found that older users were 15 times more likely to be
users 3 years later – 71 times more likely in the case of
antidepressant drugs – whereas the fact of being depressed
increased the likelihood of drug use at follow-up by 4.7
times.
Thus, if most psychotropic drug use among the elderly
transforms into long-term use, the process of transforma-
tion itself requires more observation and explanation,
again by means of longitudinal research. Immediate prob-
lems leading to the first prescription of a psychotropic
drug, such as psychological distress or insomnia, might
have little relevance among long-term users. Possibly,
drug dependence has developed among some long-term
users and sustains long-term consumption [41]. The six-
month cut-off period habitually used to distinguish short-
from long-term consumption in studies may be too long
if dependence is taken into account, as patterns of physi-
ological and psychological dependence may already have
Table 3: The association between mental health variables and psychotropic drug use
Study Results
65Allard et al. (1995), n = 500 In bivariate analysis, drug use negatively correlated with morale (r = -0.32, p < 0.001)
6 Blazer et al. (2000), n = 4,162 In multivariate logistic regression, benzodiazepine use significantly associated with depressive symptoms at 
10-year follow-up (OR: 2.13, p < 0.05)
68 Dealberto et al. (1997), n = 2,812 In multivariate logistic regression, drug use significantly associated with depressive symptoms at 6-year 
follow-up (OR: 2.78, p < 0.001)
69 Gustafsson et al. (1996), n = 421 In LISREL model, drug use positively correlated (0.63) with poor mental health (chi2 = 3.38, p = 0.33)
94 Paterniti et al. (1998), n = 1,389 In multivariate logistic regression, drug users 4 times more likely to report anxious and depressive 
symptoms than non-users (OR: 4.0, CI: 2.5–6.5)
63 Gleason et al. (1998), n = 5,181 In multivariate logistic regression, benzodiazepine users 7 times more likely to report emotional or 
nervous problems than non-users (OR: 6.66, CI 5.1, 8.7)
74 Taylor et al. (1998), n = 5,222 Depressive symptoms multiply by 3 the likelihood of using hypnotics and by 5.1 the likelihood of using 
anxiolytics. Anxious symptoms multiply by 4.2 the likelihood of using hypnotics and by 3 of using 
anxiolytics.BMC Nursing 2004, 3:3 http://www.biomedcentral.com/1472-6955/3/3
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become established within such a time frame. However,
current studies have not taken into account the depend-
ence issue. For instance, one can wonder how withdrawal
symptoms are influencing beginning and long-term users
of psychotropic drugs. Fear of withdrawal symptoms
might explain long-term use of a certain percentage of eld-
erly users. In one previous study, 71% of middle-aged psy-
chotropic drug users wanted to stop consuming these
medications, but half of them feared stopping because of
withdrawal symptoms [47]. It seems desirable to increase
knowledge on this aspect of the phenomenon among
older people, given the well documented potential of ben-
zodiazepines to provoke dependence.
It also appears that over the past decade, the use of mixed
samples of users and non-users of psychotropic drugs has
provided little information about older consumers them-
selves. Although comparison is essential for understand-
ing, perhaps more studies should target older drug users
exclusively. For instance, we know of no study examining
mental health outcomes of older psychotropic drugs users
over time. One might deem it illogical if no studies had
been conducted on the long-term effects of antihyperten-
sive medication on blood pressure. Grad [101] made the
same observation when commenting on the few empirical
studies of the impact of long-term use of benzodiazepines
on the quality of sleep of community-dwelling older
persons.
Mental health status, distress, and psychological well-being
The concepts of mental health, psychological distress,
depression, and social support are often studied in rela-
tion to psychotropic drug use, but operationalized differ-
ently across studies. For instance, in the body of studies
here reviewed, mental or emotional state is generally
measured by standardized, self-rated scales that focus on
the manifestation or experience of various symptoms of
psychological or bodily distress, or by structured diagnos-
tic interviews aiming to identify mental disorders accord-
ing to official diagnostic criteria. In all, at least 12 different
instruments or scales, 4 different systems of diagnostic cri-
teria (ICD-9 and ICD-10, DSM-III-R and DSM-IV), and 3
unstructured open questions were used in 18 studies to
measure concepts identified as depression (12 studies),
anxiety (6 studies), psychological distress, mental disor-
ders, life events (3 studies each), psychiatric syndromes (2
studies each), and morale, nervous or emotional disor-
ders, melancholy, nerves, emotional condition, dementia,
and sleep problems (1 study each). This variability in con-
cepts and instruments surely impacts the variability of
observed relationships between drug use and mental
health status (Table 1).
In addition, it is relevant to ask whether the sole use of
scales measuring psychiatric symptoms is appropriate to
understand psychotropic drugs use among older people.
As discussed, the rate of mental disorders, including sleep
problems, is lower among older than middle-aged adults,
and largely outpaces their use of psychotropic medica-
tions. This suggests that many older people are prescribed
psychotropic drugs for mild to moderate psychological
difficulties that would not qualify as DSM mental disor-
ders, and that might not produce significant impairment
in daily functioning. For example, in two studies [61,79],
while drug users displayed more depressive symptoms
than non-users according to the Center for Epidemiologic
Studies Depression scale (CES-D), their scores did not
reach the standard threshold of 16 points necessary for a
diagnosis of depression. Results such as these suggest that
scales less oriented to symptoms, distress, or disorder,
such as measures of psychological well being that focus on
so-called "positive" psychological dimensions such as
self-acceptance, autonomy, relationships, and purpose in
life [102-104], should supplement traditional-type scales.
Psychological well-being is not merely the reverse of psy-
chological distress, and the relationship of psychological
well-being to symptoms of distress is complex [105]. No
scale of psychological well-being was used in any of the
reviewed reports. However, in one recent study of older
persons, Guerette [106] found that among several meas-
ures of mental status, measures of psychological well-
being produced the strongest associations with benzodi-
azepine use.
Measures of psychotropic drug use
Some conflicting or ambiguous results across studies can
be attributed to how psychotropic drug use should be
measured. Two issues are discussed here: what drug
classes to include, and what time period of use to
consider.
Depending on the study, one or more different classes of
drugs are included among the substances measured as
psychotropic medications, although, for example, indica-
tions for the prescription of benzodiazepines differ from
those for the prescription of neuroleptics. Using a com-
posite variable of any psychotropic drug use when
examining the association with relevant sociodemo-
graphic factors or life conditions probably affects the
observed association and consequently our understand-
ing of the phenomenon. It would seem better to deter-
mine separately what variables are associated with
benzodiazepine, antidepressant, and other drug use. Ben-
zodiazepines warrant careful attention, as these drugs may
be classified as anxiolytics, sedatives, hypnotics, and anti-
convulsants–and we would not expect logically the corre-
lates of anticonvulsant use in the elderly to resemble those
of hypnotic use. In addition, researchers rarely specify
which drugs they classify as "minor tranquilizers," or how
they distinguish between "anxiolytics" and "sedatives."BMC Nursing 2004, 3:3 http://www.biomedcentral.com/1472-6955/3/3
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These definitional issues have long existed in pharma-
coepidemiology and we should not expect them to be
solved in these studies, but without assurances that drug
categories do not overlap, measures of the dependent var-
iable occasionally remain imprecise.
The average prevalence of neuroleptic drug use among
community-dwelling older persons, estimated at 3.1%
from six studies with probability samples, deserves com-
ment in this respect. It has been common wisdom that
such drug use has been rare except in institutionalized
samples. The studies also confirm that the main psycho-
tropic drugs prescribed to seniors are benzodiazepines
and antidepressants. However, most of these studies, con-
ducted in the early 1990s, probably missed the increased
popularity of atypical neuroleptics. These drugs have so
far enjoyed a reputation as less toxic drugs than conven-
tional neuroleptics, encouraging their prescription among
the older age group [98]. Several problems associated with
benzodiazepine use among seniors are not associated
with neuroleptics. However, all neuroleptics carry their
own substantial risks of adverse effects, such as tardive
dyskinesia and cognitive dysfunction (conventionals) and
weight gain and diabetes (atypicals) [107,108]. In future
studies, investigators will probably need to examine the
prevalence of these drugs' use among the elderly. The cat-
egory of reversible cholinesterase inhibitors, also known
as anti-dementia, anti-Alzheimer's, or "cognition enhanc-
ers," is also unmentioned in any of the reviewed studies.
Introduced in the mid-1990s, drugs such as donazepil and
rivastigmine are increasingly prescribed to community-
dwelling elderly showing subtle signs of dementia and
simple forgetfulness (often termed "mild cognitive
decline") according to a preventive ethos [109].
The second measurement issue to consider relates to the
period of time for which data are collected, a source of
confound noted by other reviewers [41,42,110,111]. In
the 30 studies, temporal windows varied widely, from
"current use" (4 studies), "current and past use" (1 study),
"regular use" (2 studies), two days (2 studies), one week
(1 study) two weeks (3 studies), one month (3 studies),
three months (5 studies), and one year (7 studies). In two
studies this period is undefined. When drug utilization is
measured based on more than a week, one risks inflating
the prevalence rate by including consumers who no
longer use the drugs. Conversely, one risks omitting occa-
sional users when referring to the last two days only [45].
Graham and Vidal-Zeballos [42] suggested asking
respondents about short-term consumption (past 2 days
and "recent use") and about long-term use (past year).
This suggestion does not however solve problems of inac-
curate self-report. Studies have found that older persons
frequently hide or deny their use of psychotropic drugs
[112-114].
To avoid these pitfalls, researchers in six studies deter-
mined psychotropic drug use according to municipal, pro-
vincial, state or national prescription databases held by
government agencies or health maintenance organiza-
tions. The number of prescriptions, however, can greatly
differ from actual drug consumption [16]. For example,
about 50% of the elderly do not comply with their pre-
scription regimen [115,116]. and an unknown propor-
tion share their pills with relatives or friends [85].
Finally, researchers in at least 10 studies measured drug
use by inspecting medication containers at the home of
the respondent [83]. This method confirms that drugs
have been obtained but leaves the compliance problem
unresolved. A good rationale exists nonetheless to encour-
age this method, probably the most reliable way to get as
close as possible to actual consumption [55,63,83,111].
Given that one third of studies in this review used this
method suggests that its cost may be relatively acceptable.
Interestingly, only two studies used telephone surveys.
Owing to their relatively lesser cost than personal inter-
views, and since the development of reliable technologies,
telephone surveys using random-digit dialing and ran-
dom-select dialing are increasingly used to contact
respondents in health related surveys.
Conclusions
Without being exhaustive, the present literature review is
comprehensive and the range of reports, methods, sam-
ples, and geographical locations provides a reasonably
solid base to support most recommendations. This review
was limited to empirical studies. To better understand the
phenomenon of psychotropic drug use among commu-
nity-dwelling elderly, it is desirable that historical, psy-
chological, sociological, political and regulatory, as well
as medical aspects of the phenomenon be considered.
While some factors are clearly associated with psycho-
tropic drug use in the reviewed studies (such as race, prox-
imity to health centers, sleep complaints, and health
perception), few investigators test specific hypotheses to
account for the associations. For example, sparse work
focuses on cultural factors that might explain drug use dis-
parities between Whites and African-Americans. Similarly,
with most drug users being long-term and most drug treat-
ments for insomnia losing their effectiveness with long-
term use, the strong association between sleep complaints
and drug use needs thorough examination.
One of the least studied aspects of the phenomena in the
reviewed studies concerns the role of health care profes-
sionals. Physicians, nurses, and pharmacists all interact
significantly with community-dwelling older persons,
especially with those who take psychotropic medications.
Only through a health care professional such as a physi-BMC Nursing 2004, 3:3 http://www.biomedcentral.com/1472-6955/3/3
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cian and a pharmacist would the vast majority of older
people obtain a psychotropic drug to relieve a sleep prob-
lem. Recently, the Internet and mail-order pharmacies
without face-to-face interaction have facilitated individu-
als' access to prescription drugs. Each professional's role,
as mentioned, is also likely to alter as the individual's
phase of consumption transforms from short-to long-
term. Researchers must face the challenge to incorporate
variables related to health care professionals' attitudes and
behaviors, as well as to new modes of distribution of psy-
chotropic drugs to consumers, in their study of the
phenomenon.
Approximately one third of community-dwelling older
persons use psychotropic medications. If the rate of psy-
chiatric disorders among a population serves as a guide-
line, then obviously older persons' use of psychiatric
drugs far outpaces these drugs' standard indications and
has extended into areas where drugs have little docu-
mented effectiveness. Viewed in this light, the ubiquitous
phenomenon of long-term psychotropic drug use should
evoke concern and caution. The discipline of nursing can
definitely contribute to the rational use of these agents
among older people. As suggested in this review, research-
ers do not still fully grasp the dynamics of psychotropic
drug use among this population and creative and rigorous
research from several disciplines, and from interdiscipli-
nary perspectives, is needed. However, nurses concerned
by the problem of the overuse of medication and its
adverse consequences can already implement and evalu-
ate programs to educate older people and allied health
care and social service professionals about the risks of psy-
chotropic drugs and alternatives to drugs for the manage-
ment of everyday anxiety, loneliness, depression, and
especially insomnia. Nurses can also actively implement
and evaluate drug withdrawal programs aimed at long-
term users who have had difficulty in withdrawing, and
especially at short-term users who might soon be trapped
into dependency and thus long-term use. Conversely,
diverse patterns of psychotropic drug use undoubtedly
exist among older persons, and positive patterns of use,
emanating from users' own experiences and discoveries,
need to be documented and disseminated.
Competing interests
None declared.
Authors' contributions
PV and DC conducted the literature review and drafted the
manuscript. SL and JC revised the literature review and
subsequent drafts. All authors read and approved the final
manuscript.
Additional material
Acknowledgement
The authors thank the Conseil Québécois de la recherche sociale, the Fac-
ulty of nursing of Laval University and of University of Montreal, the Uni-
versity institute of social gerontology of Quebec, the Canadian nurses 
foundation, the research group on social aspects of health and prevention 
and the College of health and urban affairs of Florida International Univer-
sity for their financial support.
References
1. Glazer GB, Zawadski RT: Use of psychotropic drugs among the
aged revisited. Journal of Psychoactive Drugs 1981, 13:195-198.
2. Jenkins BL: A case against "sleepers.". Journal of Gerontological
Nursing 1976, 2:10-13.
3. Health Canada: Canada's Alcohol and Other Drugs Survey. Ottawa 1994.
4. Tamblyn RM, McLeod PJ, Abrahamowicz M, Monette J, Gayton DC,
Berkson L, Dauphinee WD, Grad RM, Huang AR, Isaac LM, Schnarch
BS, Snell LS: Questionable prescribing for elderly patients in
Quebec. Canadian Medical Association Journal 1994, 150:1801-1809.
5. Wancata J, Benda N, Meise U, Müller C: Psychotropic drug intake
in residents newly admitted to nursing homes. Psychopharma-
cology 1997, 134:115-120.
6. Blazer D, Hybels C, Simonsick E, Hanlon JT: Sedative, hypnotic,
and antianxiety medication use in an aging cohort over ten
years: A racial comparison. Journal of the American Geriatrics Society
2000, 48:1073-1079.
7. Isacson D, Carsjo K, Bergman U, Blackburn JL: Long-term use of
benzodiazepines in a Swedish community: An eight-year
follow-up. Journal of Clinical Epidemiology 1992, 45:429-436.
8. Allen RM: Tranquilizers and sedative/hypnotics: Appropriate
use in the elderly. Geriatrics 1996, 47:57-88.
9. Baillargon L, Landreville P, Verreault R, Beauchemin JP, Grégoire JP,
Morin CM: Discontinuation of benzodiazepines among older
insomniac adults treated with cognitive-behavioral therapy
combined with gradual tapering: A randomized trial. Cana-
dian Medical Association Journal 2003, 169:1015-1020.
10. Baker R, Shaw EJ: Audit protocol: Benzodiazepine Prescribing
in Primary Care. CT17. Leicester: Clinical Governance Research &
Development Unit, Department of General Practice & Primary Health Care,
University of Leicester 2001.
11. Closser MH: Benzodiazepines and the elderly: A review of
potential problems.  Journal of Substance Abuse Treatment 1991,
8:35-41.
12. Kupfer DJ, Reynolds CF: Management of insomnia. New England
Journal of Medicine 1997, 336:341-346.
13. Lader MH: Limitations on the use of benzodiazepines in anxi-
ety and insomnia: Are they justified?  European Journal of
Neuropsychopharmacology 1999, Suppl 6:S399-S405.
Additional File 1
Characteristics of 32 empirical reports on psychotropic drug use among 
community-dwelling older persons, 1990–2001. Reports on psychotropic 
drug use among community-dwelling older persons.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6955-3-3-S1.doc]
Additional File 2
Factors associated with psychotropic drug use among community-dwelling 
older persons in 32 empirical reports, 1990–2001. Factors associated with 
psychotropic drug use among community-dwelling older persons.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6955-3-3-S2.doc]BMC Nursing 2004, 3:3 http://www.biomedcentral.com/1472-6955/3/3
Page 11 of 13
(page number not for citation purposes)
14. Mah L, Upshur REG: Long term benzodiazepine use for insom-
nia in patients over the age of 60: Discordance of patient and
physician perceptions. BMC Family Practice 2002, 3:9.
15. Mcleod PJ, Hung AR, Tamblyn AR, Gayton DC: Defining inappro-
priate practice in prescribing for elderly people: A national
consensus panel.  Canadian Medical Association Journal 1997,
156:385-391.
16. Thomson M, Smith WA: Prescribing benzodiazepines for nonin-
stitutionalized elderly. Canadian Family Physician 1995, 41:792-798.
17. Walsh JK, Hartman PG, Kowall JP: Insomnia. In Sleep Disorders Med-
icine: Basic Science, Technical Considerations and Clinical Aspects Edited
by: Chokroverty S. Boston: Butterworth-Heinemann; 1994:219-239. 
18. Petrovic M, Vandierendonck A, Mariman A, Maele GV: Personality
traits and socio-epidemiological status of hospitalized eld-
erly benzodiazepine users. International Journal of Gerontological
Psychiatry 2002, 17:733-738.
19. Berg S, Dellasega C: The use of psychoactive medications and
cognitive function in older adults. Journal of Aging and Health
1996, 8:136-149.
20. Cooper JW: Drug-related problems in the elderly patient.
Pharmacology and Older People 1994, Summer:19-27.
21. Tamblyn RM: Medication use in seniors: Challenges and
solutions. Therapie 1996, 51:269-282.
22. Blazer D: The epidemiology of depression in late life. Journal of
Geriatric Psychiatry 1990, 22:35-52.
23. Blazer D, Hughes DC, George LK: The epidemiology of depres-
sion in an elderly community population. Gerontologist 1987,
27:281-287.
24. Cappeliez P: La dépression, la solitude et le deuil chez les per-
sonnes âgées. [Depression, loneliness and grief among older persons].
Santé mentale et vieillissement, écrits en gérontologie. Canada: Conseil con-
sultatif national sur le troisième âge .
25. Folks DG, Fuller WC: Anxiety disorders and insomnia in geri-
atric patients. Geriatric Psychiatry 1997, 20:137-164.
26. Jorm AF: Does old age reduce the risk of anxiety and depres-
sion? Review of epidemiological studies across the adult life
span. Psychological Medicine 2000, 30:11-22.
27. Myers JK, Weissman MM, Tischler GL, Holzer CE, Leaf PJ, Orvaschel
H, Anthony JC, Boyd JH, Burke JD: Six-month prevalence of psy-
chiatric disorders in three communities.  Archives in General
Psychiatry 1984, 14:959-967.
28. Ohayon MM, Caulet M: Insomnia and psychotropic drug con-
sumption.  Progress in Neuro-Psychopharmacology and Biological
Psychiatry 1995, 19:421-431.
29. Papillon M-J, Laurier C, Bernard L, Baril J: Consommation de
médicaments [Use of medicines]. In Enquête sociale et de santé
Collection la santé et le bien-être. Québec: Institut de la statistique; Ch. 22
1998.
30. Skoog I, Nilsson L, Landahl S, Steen B: Mental disorders and the
use of psychotropic drugs in an 85-year-old urban
population. International Psychogeriatrics 1993, 5:33-48.
31. Aparasu RR, Mort JR, Sitzman S: Psychotropic prescribing for the
elderly in office-based practice.  Clinical Therapy 1998,
20:603-616.
32. Stewart RB: Benzodiazepine use in an ambulatory elderly pop-
ulation: A 14-year overview.  Clinical Therapeutics 1994,
16:118-124.
33. Mishara BL, McKim WA: Drogues et vieillissement. [Drugs and
aging]. Chicoutimi (Québec): Gaëtan Morin 1989.
34. Mishara BL, Legault A: La consommation de médicaments chez
les personnes âgées: une perspective psychosociale [Use of
medication among elderly people: A psychosocial perspec-
tive]. Rapport de recherche présenté au Conseil québécois de la recherche
sociale 1999.
35. Isacson D, Haglund B: Psychotropic drug use in a swedish com-
munity: The importance of demographic and socioeconomic
factors. Social Science and Medicine 1988, 26:477-483.
36. Laurier C, Dumas J, Grégoire J-P: Factors related to benzodi-
azepine use in Quebec: A secondary analysis of survey data.
Journal of Pharmacoepidemiology 1992, 2:73-86.
37. Morgan K: Sedative-hypnotic drug use and ageing (a review).
Archives of Gerontology and Geriatrics 1983, 2:181-199.
38. Ohayon MM, Caulet M, Priest RG, Guilleminault C: Psychotropic
medication consumption patterns in the UK general
population. Journal of Clinical Epidemiology 1998, 51:273-283.
39. Van Hulten R, Teeuw KB, Bakker AB, Bakker A, Leufkens HG: Char-
acteristics of current benzodiazepine users as indicators of
differences in physical and mental health. Pharmacy World &
Science 2000, 22:96-101.
40. Harrington C, Tompkins C, Curtis M, Grant L: Psychotropic drug
use in long-term care facilities: a review of the literature. Ger-
ontologist 1992, 32:822-833.
41. Cohen D, Collin J: Les toxicomanies en lien avec les médica-
ments psychotropes chez les personnes âgées, les femmes et
les enfants: Recension et analyse des écrits. [Substance depend-
ence associated with psychotropic medications among the elderly, women
and children: Review and analysis of the literature. Quebec: Ministère de la
santé et des services sociaux 2000.
42. Graham K, Vidal-Zeballos D: Analyses of use of tranquilizers and
sleeping pills across five surveys of the same population
(1985–1991): The relationship with gender, age and use of
other substances. Social Science and Medicine 1998, 46:381-395.
43. Pérodeau G, Jomphe HA, Hay-Paquin L, Amyot É: Les psycho-
tropes et le vieillissement normal : Une perspective psycho-
sociale et socio-économique [Psychotropic drugs and
normal aging: A psychosocial and socieconiomic
perspective]. Canadian Journal on Aging 1996, 15:559-583.
44. Helman CG: Tonic, fuel, food: Social and symbolic aspects of
the long-term use of psychotropic drugs. In Tranquillisers, Social,
Psychological, and Clinical Perspectives Edited by: Gabe J, Williams P.
New York: Tavistock; 1986:199-226. 
45. Weyerer S, Dilling H: Psychiatric and physical illness, sociode-
mographic characteristics and use of psychotropic drugs in
the community: Results from the upper Bavarian Field
Study. Journal of Clinical Epidemiology 1991, 44:303-311.
46. Barat I, Andreasen F, Damsgaard EMS: The consumption of drugs
by 75-year-old individuals living in their own homes. European
Journal of Clinical Pharmacology 2000, 56:501-509.
47. Ettore E, Klaukka T, Riska E: Psychotropic drugs: Long-term use,
dependency and the gender factor. Social Science and Medicine
1994, 39:1667-1673.
48. Egberts ACG, Leufkens HGM, Hofman A, Hoes AW: Incidence of
antidepressant drug use in older adults and association with
chronic diseases: The Rotterdam Study.  International Clinical
Psychopharmacology 1997, 12:217-223.
49. Mamdani M, Herrmann N, Austin P: Prevalence of antidepressant
use among older people: Population-based observations. Jour-
nal of the American Geriatrics Society 1999, 47:1350-1353.
50. Pérodeau G, King S, Ostoj M: Stress and psychotropic drug use
among the elderly: An exploratory model. The Canadian Journal
of Aging 1992, 11:347-369.
51. Grossberg GT, Grossberg JA: Epidemiology of psychotherapeu-
tic drug use in older adults.  Clinics in Geriatric Medicine 1998,
14:1-5.
52. Cafferata GL, Kasper J, Bernstein A: Family roles, structure, and
stressors in relation to sex differences in obtaining psycho-
tropic drugs. Journal of Health and Social Behavior 1983, 24:132-143.
53. Kirby M, Denihan A, Bruce I, Radic A, Coakley D, Lawlor BA: Ben-
zodiazepine use among the elderly in the community. Interna-
tional Journal of Geriatric Psychiatry 1999, 14:280-284.
54. Hohmann AA: Gender bias in prescribing in primary care. Med-
icine Care 1989, 27:478-490.
55. Jorm AF, Grayson D, Creasey H, Waite L, Broe GA: Long-term
benzodiazepine use by elderly people living in the
community. Australian and New Zealand journal of Public Health 2000,
24:7-10.
56. Mellinger GD, Balter MD, Chase C, Manheimer DI: Patterns of psy-
chotherapeutic drug use among adults in San Francisco.
Archives in General Psychiatry 1971, 25:385-394.
57. Parry HJ, Balter MB, Mellinger CD, Cisin IH, Manheimer DI: National
patterns of psychotherapeutic drug use.  Archives in General
Psychiatry 1973, 28:769-783.
58. Cooperstock R, Parnell P: Research on psychotropic drug use: A
review of findings and methods. Social Science and Medicine 1982,
16:1179-1196.
59. Cooperstock R: Sex differences in the use of mood modifying
drugs: An explanatory model. Journal of Health and Social Behavior
1971, 12:228-244.
60. Brown SL, Salive ME, Guralnik JM, Pahor M, Chapman DP, Blazer D:
Antidepressant use in the elderly: Association with demo-BMC Nursing 2004, 3:3 http://www.biomedcentral.com/1472-6955/3/3
Page 12 of 13
(page number not for citation purposes)
graphic characteristics, health-related factors, and health
care utilization. Journal of Clinical Epidemiology 1995, 48:445-453.
61. Mayer-Oakes SA, Kelman G, Beers MK, De Jong F, Matthias R,
Atchison A, Lubben JE, Schweitzer SO: Benzodiazepine use in
older, community-dwelling Southern Californians: Preva-
lence and clinical correlates. The Annals pf Pharmacotherapy 1993,
27:416-421.
62. Swartz M, Landerman R, George LK, Melville ML, Blazer D, Smith K:
Benzodiazepine anti-anxiety agents: Prevalence and corre-
lates of use in Southern community. American Journal of Public
Health 1991, 81:592-596.
63. Gleason PP, Schultz R, Smith NL, Newsom JT, Kroboth FJ, Psaty BM:
Correlates and prevalence of benzodiazepine use in commu-
nity-dwelling elders.  Journal of General Internal Medicine 1998,
13:243-250.
64. McNutt L-A, Coles FB, McAuliffe T, Baird S, Morse DL, Strogatz DS,
Baron RC, Eadie JL: Impact of regulation on benzodiazepine
prescribing to a low income elderly population, New York
State. Journal of Clinical Epidemiology 1994, 47:613-625.
65. Allard J, Allaire D, Leclerc G, Langlois S-P: The influence of family
and social relatioships on the consumption of psychotropic
drugs by the elderly. Archives of Gerontology and Geriatrics 1995,
20:193-204.
66. Antonijoan RM, Barbanoj MJ, Torrent J, Jane F: Evaluation of psy-
chotropic drug consumption related to psychological dis-
tress in the elderly: Hospitalized vs nonhospitalized.
Neuropsychobiology 1990, 23:25-30.
67. Blazer D, Hybels C, Simonsick EM, Hanlon JT: Marked differences
in antidepressant use by race in an elderly community sam-
ple: 1986–1996. American Journal of Psychiatry 2000, 157:1089-1094.
68. Dealberto MJ, Seeman T, McAvay GJ, Berkman L: Factors related
to current and subsequent psychotropic drug use in an eld-
erly cohort. Journal of Clinical Epidemiology 1997, 50:357-364.
69. Gustafsson TM, Isacson DGL, Thorslund M, Sörbom D: Factors
associated with psychotropic drug use among the elderly liv-
ing at home. Journal of Applied Gerontology 1996, 15:238-254.
70. Larose D: Les habitudes de consommation de psychotropes
chez les personnes âgées [Psychotropic drug use habits
among older persons].  Santé mentale au Québec 1996,
21:1:291-296.
71. Newman SC, Hassan AI: Antidepressant use in the elderly pop-
ulation in Canada: results from a national survey. Journal of
Gerontology: Medical Sciences 1999, 54A:M527-M530.
72. Paterniti S, Dufouil C, Bisserbe J-C, Alperovitch A: Anxiety, depres-
sion, psychotropic drug use and cognitive impairment. Psycho-
logical Medicine 1999, 29:421-428.
73. Ried LD, Johnson RE, Gettman DA: Benzodiazepine exposure
and functional status in older people. Journal of the American Ger-
iatrics Society 1998, 46:71-77.
74. Taylor S, McCracken CFM, Wilson KCM, Copeland JRM: Extent and
appropriateness of benzodiazepine use.  British Journal of
Psychiatry 1998, 173:433-438.
75. Bogart LM, Bird ST, Walt LC, Delahanty DL, Figler JL: Association
of stereotypes about physicians to health care satisfaction,
help-seeking behaviour, and adherence to treatment. Social
Science & Medicine 2004, 58:1049-1058.
76. Flaskerud JH: Ethnicity, culture and neuropsychiatry. Issues in
Mental Health Nursing 2000, 21:5-29.
77. Knipe E: Culture, Society and Drugs: The Social Science
Approach to Drug Use. Illinois: Waveland Press; 1995. 
78. Brown CM, Nichols-English G: Dealing with patient diversity in
pharmacy practice. The Online Newsmagazine for pharmacist 1999,
September:20.
79. Pérodeau G, Galbaud du Fort G: Psychotropic drug use and the
relation between social support, life events, and mental
health in the elderly. Journal of Applied Gerontology 2000, 19:23-41.
80. Sleath B, Svarstad B, Roter D: Patient race and psychotropic pre-
scribing during medical encounterse.  Patient Education and
Counseling 1998, 34:231-242.
81. Holahan J, Kim J: Why does the number of uninsured Ameri-
cans continue to grow? Health Affairs 2000, 19:188-96.
82. Ministère de la Santé et des Services sociaux: L'utilisation
rationelle des médicaments chez les personnes âgées.
Stratégie d'action. [The rational use of medications among older per-
sons: Plan of action]. Québec: Bibliothèque nationale du Québec 1994.
83. Graham K, Clarke D, Bois C, Car ver  V, Marshman J, Smythe C:
Depressant medication use by older persons in the broader
social context relating to use of psychoactive substances.
Journal of Substance Misuse 1998, 3:161-169.
84. Aparasu RR, Mort JR, Brandt H: Psychotropic prescription use by
community-dwelling elderly in the United States. Journal of the
American Geriatrics Society 2003, 51:671-677.
85. Simonson W: Medications & the Elderly. A Guide for Promot-
ing Proper Use. Maryland: Aspen Publication; 1984. 
86. Lemoigne P: Psychotropic drug use: Towards a medical treat-
ment of isolation. The International Scope Review 2003, 9:69-99.
87. Harris JR, Pedersen NL, Stacey C, McClearn GE, Nesselroade JR:
Age differences in etiology of the relationship between life
satisfaction and self-rated health.  Journal of Aging and Health
1992, 4:349-368.
88. Langemo L, Volden P, Oechsle LL, Adamson M: Explicating the
relationship of health measures and self-esteem to exercise
practices in adults. Health Education 1990, 21:7-11.
89. Misra R, Alexy B, Panigraphi B: The relationships among self-
esteem, exercise, and self-rated health in older women. Jour-
nal of Women & Aging 1996, 8:81-94.
90. Quinn WH: Personal and family adjustment in later life. Journal
of Marriage and the Family 1983, 45:57-73.
91. Arinen S, Häkkinen U, Klaukka T, Klavus J, Lehtonen R, Aro S: Health
and the use of health services in Finland. Main findings of the Finnish Health
Care Survey 1995/96 and changes from 1987. Helsinki: SVT Health 1998.
92. Mishara BL: L'écologie familiale et la consommation de médi-
caments chez les personnes âgées: Commentaires sur un
facteur important ignoré dans les recherches et les projets
de prévention [Family ecology and psychotropic drug use
among older persones: comments on an important factor
ignored in research and prevention projects]. Santé mentale au
Québec 1997, 22:200-215.
93. Robidas G: La problématique Santé-personnes âgées, Région
des Laurentides. Volume 1. [The issue of health and older persons,
Laurentides Region]. District de santé communautaire Saint-Jérôme 1987.
94. Paterniti S, Bisserbe JC, Alpérovitch A: Psychotropic drugs, anxi-
ety and depression in the elderly population EVA study. Revue
d'épidémiologie et de santé publique 1998, 46:253-262.
95. American Psychiatric Association: Diagnostic and Statistical
Manual of Mental Disorders, Third Edition, Revised. (DSM-III-
R). Washington, DC: APA 1987.
96. Gibson RM, Waldo DR: National health expenditures. Health
Care Financing Review 1981, 3:1-54.
97. Soumerai SB: Improving drug prescribing in primary care
settings. Milbank Quaterly 1989, 67:269.
98. Collin J, Damestoy N, Lalande R: La construction d'une ration-
nalité: Les médecins face à la prescription de psychotropes
aux personnes âgées [The construction of a rationality: Phy-
sicians and psychotropic drug prescription to the elderly].
Sciences sociale et Santé 1999, 17:31-50.
99. Davidson W, Molley W, Somers G, Bedard M: Relation between
physician characteristics and prescribing to elderly people in
New Brunswick.  Canadian Medical Association Journal 1994,
150:917-921.
100. Ohayon MM, Caulet M, Lemoine P: Sujets âgés, habitudes de
sommeil et consommation de psychotropes dans la popula-
tion française [Aged subjects, sleep habits, and psychotropic
drug use in the French population].  L'Encéphale 1996,
22:337-350.
101. Grad MR: Benzodiazepines for insomnia in community-dwell-
ing elderly: Areview of benefit and risk. Journal of Family Practice
1995, 41:473-481.
102. Ryff CD, Singer B: Psychological well-being: Meaning, measure-
ment, and implications for psychotherapy research. Psycho-
therapy & Psychosomatics 1996, 65:14-23.
103. Massé R, Poulin C, Dassa C, Lambert J, Bélair S, Battaglini A: Élabo-
ration et validation d'un outil de mesure du bien-être psy-
chologique: L'É.M.M.B.E.P. [Construction and validation of a
measure of psychological distress]. Revue Canadienne de Santé
Publique 1998, 89:352-357.
104. Massé R, Poulin C, Dassa C, Lambert J, Bélair S: Élaboration et val-
idation d'un outil de mesure de la détresse psychologique
dans une population non clinique de Québécois francoph-
ones [Construction and validation of a measure of psycho-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Nursing 2004, 3:3 http://www.biomedcentral.com/1472-6955/3/3
Page 13 of 13
(page number not for citation purposes)
logical distress in a non-clinical population of francophone
Quebeckers]. Revue Canadienne de Santé Publique 1998, 89:183-187.
105. Ruini C, Ottolini F, Rafanelli C, Tossani E, Ryff CD, Fava GA: The
relationship of psychological well-being to distress and
personality. Psychotherapy & Psychosomatics 2003, 72:268-275.
106. Guerette A: La santé mentale des personnes âgées consom-
mant régulièrement des benzodiazépines [The mental
health of older persons regularly using benzodiazepines].
PhD thesis. Université Laval, École de psychologie 2001.
107. Falsetti AE: Risperidone for control of agitation in dementia
patients.  American Journal of Health-System Pharmacy 2000,
57:862-870.
108. Lanctôt KL, Best TS, Mittmann N, Liu B, Oh PI, Einarson TR, Naranjo
CA: Efficacy and safety of neuroleptics in behavioral disor-
ders associated with dementia. Journal of Clinical Psychiatry 1998,
59:550-561.
109. Dubois B, Beato R, Kalafat M: Avant la démence..., ou les limites
du concept de trouble cognitive léger (MCI: mild cognitive
impairment) [Before dementia..., or the limits of the con-
cept of mild cognitive impairment].  Medicine/Sciences 2002,
18:775-779.
110. Mishara BL, McKim WA: Methodological issues in surveying
older persons concerning drug use. International Journal of the
Addictions 1993, 28:305-326.
111. Landry JA, Smyer MA, Tubman JG, Lago DJ, Roberts J, Simonson W:
Validation of two methods of data collection of self-reported
medicine use among elderly. Gerontologist 1988, 28:672-676.
112. Benkert O, Graf-Morgenstern M, Hillert A, Sandmann J: Public opin-
ion on psychotropic drugs: An analysis of the factors influ-
encing acceptance or rejection. Journal of Nervous and Mental
Disease 1997, 185:151-158.
113. Grymonpre RE, Badger M, Tabisz E, Jacyk WR, Powell C: The devel-
opment of a prescription drug dependence screen for older
adults. Canadian Journal of Hospital Pharmacy 1996, 49:7-12.
114. Spagnoli A, Ostino G, Borga AD, D'Ambrosio R, Magiorotti P,
Todisco E, Prattichizzo W, Pia L, Comelli M: Drug compliance and
unreported drugs in the elderly. Journal of the American Geriatric
Society 1989, 37:92-98.
115. Franson KL, Smith SL: Compliance: Problems and
opportunities. Clinics in Geratric Medicine 1998, 14:7-16.
116. Salzman C: Medication compliance in the elderly. Journal of Clin-
ical Psychiatry 1995, 56:18-23.
117. Santé Québec: Et la santé ça va en 1992–1993? Rapport de
l'enquête sociale et de santé, volume 1. How is health in 1992–
1993? Report of the social and health survey, volume 1]. Québec: Santé
Québec 1995.
118. Tamblyn R: Rapport d'évaluation de l'impact du régime
général d'assurance-médicaments. [Evaluation of the impact of the
medication-insurance program]. Québec: Ministère de la Santé et des Serv-
ices sociaux du Québec 1999.
119. Cans C, Rotily M: La consommation de psychotropes en popu-
lation générale dans le département de l'Isère. [Psycho-
tropic drug use in the general population of Isère.]. Revue
d'Épidémiologie et de Santé Publique 1991, 39:515-522.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1472-6955/3/3/prepub